Blair William & Co. IL Acquires 169,237 Shares of PROCEPT BioRobotics Corporation $PRCT

Blair William & Co. IL boosted its holdings in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 34.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 666,442 shares of the company’s stock after acquiring an additional 169,237 shares during the period. Blair William & Co. IL’s holdings in PROCEPT BioRobotics were worth $23,785,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Advisory Services Network LLC boosted its position in shares of PROCEPT BioRobotics by 1.3% during the second quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after buying an additional 250 shares during the period. Vega Investment Solutions raised its position in PROCEPT BioRobotics by 52.0% in the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after buying an additional 265 shares during the last quarter. Frank Rimerman Advisors LLC lifted its stake in PROCEPT BioRobotics by 0.3% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 122,389 shares of the company’s stock valued at $4,368,000 after acquiring an additional 307 shares in the last quarter. RiverPark Advisors LLC lifted its stake in PROCEPT BioRobotics by 22.5% in the 2nd quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock valued at $101,000 after acquiring an additional 324 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its position in PROCEPT BioRobotics by 20.3% during the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock worth $115,000 after acquiring an additional 337 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Trading Down 4.5%

NASDAQ PRCT opened at $24.22 on Friday. PROCEPT BioRobotics Corporation has a 12 month low of $19.35 and a 12 month high of $66.85. The company has a current ratio of 6.85, a quick ratio of 5.77 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average of $29.25 and a 200-day moving average of $32.97. The company has a market cap of $1.37 billion, a PE ratio of -14.16 and a beta of 1.02.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.The firm had revenue of $76.38 million for the quarter, compared to analyst estimates of $93.70 million. During the same quarter in the previous year, the firm posted ($0.35) earnings per share. PROCEPT BioRobotics’s quarterly revenue was up 11.9% on a year-over-year basis. On average, equities research analysts anticipate that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PRCT. Wall Street Zen downgraded shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Jefferies Financial Group cut shares of PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 26th. Robert W. Baird assumed coverage on shares of PROCEPT BioRobotics in a research report on Friday. They issued a “neutral” rating and a $30.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Thursday, January 22nd. Finally, Wells Fargo & Company cut their price target on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a research report on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $40.82.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.